Search Result

Results for "

uric acid,hypoxanthine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apoptosis (1) Bacterial (1) Biochemical Assay Reagents (1) CD38 (1) CGRP Receptor (2) Cytochrome P450 (2) Drug Derivative (3) Endogenous Metabolite (19) Ferroportin (1) Fungal (1) GCGR (7) GLP Receptor (8) GLUT (3) Isotope-Labeled Compounds (3) MARCKS (2) Natriuretic Peptide Receptor (NPR) (1) NOD-like Receptor (NLR) (2) Oxidative Phosphorylation (1) Oxytocin Receptor (1) PD-1/PD-L1 (2) Peptide-Drug Conjugates (PDCs) (1) Phospholipase (1) PKC (2) PPAR (1) Reactive Oxygen Species (ROS) (12) Reference Standards (6) URAT1 (13) Vasopressin Receptor (3) Wnt (1) Xanthine Oxidase (12) β-catenin (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (5) Endocrinology (4) Infection (2) Inflammation/Immunology (19) Metabolic Disease (42) Neurological Disease (5)

By Targets:

Amyloid-β (1)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (1)

Apoptosis (1)

Bacterial (1)

Biochemical Assay Reagents (1)

CD38 (1)

CGRP Receptor (2)

Cytochrome P450 (2)

Drug Derivative (3)

Endogenous Metabolite (19)

Ferroportin (1)

Fungal (1)

GCGR (7)

GLP Receptor (8)

GLUT (3)

Isotope-Labeled Compounds (3)

MARCKS (2)

Natriuretic Peptide Receptor (NPR) (1)

NOD-like Receptor (NLR) (2)

Oxidative Phosphorylation (1)

Oxytocin Receptor (1)

PD-1/PD-L1 (2)

Peptide-Drug Conjugates (PDCs) (1)

Phospholipase (1)

PKC (2)

PPAR (1)

Reactive Oxygen Species (ROS) (12)

Reference Standards (6)

URAT1 (13)

Vasopressin Receptor (3)

Wnt (1)

Xanthine Oxidase (12)

β-catenin (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (5)

Endocrinology (4)

Infection (2)

Inflammation/Immunology (19)

Metabolic Disease (42)

Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B2130R

Uric acid (Standard)	Reference Standards Reactive Oxygen Species (ROS) Endogenous Metabolite	Inflammation/Immunology
Uric acid (Standard) is the analytical standard of Uric acid. This product is intended for research and analytical applications. Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-B2130

Uric acid Maximum Cited Publications 11 Publications Verification	Reactive Oxygen Species (ROS) Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-B2130S1

Uric acid-15N2	Endogenous Metabolite Reactive Oxygen Species (ROS)	Inflammation/Immunology
Uric acid- ¹⁵N₂ is the ¹⁵N labeled Uric acid . Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-B2130A

Uric acid sodium Maximum Cited Publications 11 Publications Verification Monosodium urate	Reactive Oxygen Species (ROS) Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Uric acid sodium (Monosodium urate), scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid sodium can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-B2130S

Uric acid-13C,15N3	Reactive Oxygen Species (ROS) Endogenous Metabolite	Inflammation/Immunology
Uric acid- ¹³C, ¹⁵N₃ is the ¹³C-labeled and ¹⁵N-labeled Uric acid. Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-W506071

3,7-Dimethyluric acid	Drug Derivative	Others
3,7-Dimethyluric acid is a methyl derivative of uric acid .

HY-B2130AR

Uric acid sodium (Standard)	Reactive Oxygen Species (ROS) Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Uric acid (sodium) (Standard) is the analytical standard of Uric acid (sodium). This product is intended for research and analytical applications. Uric acid sodium (Monosodium urate), scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid sodium can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-W780166

Uric acid-13C	Reactive Oxygen Species (ROS)	Cardiovascular Disease
Uric acid- ¹³C is the ¹³C-labeled Uric acid (HY-B2130). Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-W770183

Uric acid-13C3	Isotope-Labeled Compounds	Others
Uric acid- ¹³C₃ is ¹³C-labeled Uric acid (HY-B2130). Uric acid is the end product of purine metabolism in the human body. Uric acid can scavenge reactive oxygen species (ROS), such as singlet oxygen and peroxynitrite, and inhibit lipid peroxidation.

HY-B2130S2

Uric acid-13C5	Reactive Oxygen Species (ROS) Endogenous Metabolite Isotope-Labeled Compounds	Inflammation/Immunology
Uric acid- ¹³C₅ is the ¹³C-labeled Uric acid (HY-B2130). Radioactive isotopes labeled compounds can be used in metabolic analysis, allowing the movement of individual atoms to be precisely tracked and quantified .

HY-W011711R

Benzarone (Standard) Fragivix (Standard)	Reference Standards URAT1	Metabolic Disease
Benzarone (Standard) is the analytical standard of Benzarone. This product is intended for research and analytical applications. Benzarone (Fragivix) is a potent human uric acid transporter 1 (hURAT1) inhibitor, with an IC₅₀ of 2.8 μM in oocyte. Benzarone could lower uric acid serum levels .

HY-P2921B

Uricase, Arthrobacter globiformis Uox, Arthrobacter globiformis	Endogenous Metabolite	Metabolic Disease
Uricase, Arthrobacter globiformis is a peroxidase enzyme. It catalyzes the oxidation of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. A deficiency of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .

HY-P2921A

Uricase, Bacillus fastidious Uox, Bacillus fastidious	Endogenous Metabolite	Metabolic Disease
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .

HY-P2921C

Uricase (Recombinant) Uox (Recombinant)	Endogenous Metabolite	Metabolic Disease
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .

HY-B1514

Allantoic acid 1 Publications Verification	Endogenous Metabolite	Others
Allantoic acid is a degradative product of uric acid and associated with purine metabolism .

HY-15933

TOPS	Biochemical Assay Reagents	Others Metabolic Disease
TOPS is a chromogenic substrate. TOPS undergoes an oxidative coupling reaction with 4-aminoantipyrine in the presence of H₂O₂ and nanocrystalline cobalt selenide. TOPS is used in studies related to uric acid detection .

HY-P2755

Xanthine oxidase, Microorganism 1 Publications Verification XO; XOD	Reactive Oxygen Species (ROS)	Inflammation/Immunology Endocrinology
Xanthine oxidase, Microorganism (XO) is a xanthine oxidoreductase enzyme that generates reactive oxygen species (ROS), catalyzes the oxidation of hypoxanthine to xanthine, and further catalyzes the oxidation of xanthine to uric acid .

HY-P2755A

Xanthine oxidase, bovine milk	Reactive Oxygen Species (ROS)	Inflammation/Immunology Endocrinology
Xanthine oxidase, bovine milk is a xanthine oxidoreductase enzyme that generates reactive oxygen species (ROS), catalyzes the oxidation of hypoxanthine to xanthine, and further catalyzes the oxidation of xanthine to uric acid .

HY-P2921

Urate oxidase, Microorganism Uox	Endogenous Metabolite	Others
Urate oxidase, Microorganism (Uox), i.e., uricase, is often used in biochemical studies. Urate oxidase is a peroxisomal enzyme that catalyzes the oxidation of uric acid to allantoin in most mammals .

HY-153972

URAT1&XO inhibitor 2	URAT1 Xanthine Oxidase	Metabolic Disease Inflammation/Immunology
URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC₅₀ of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a K_i value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia .

HY-W011711

Benzarone Fragivix	URAT1 Oxidative Phosphorylation Apoptosis	Metabolic Disease
Benzarone (Fragivix) is an oral inhibitor of human urate transporter 1 (hURAT1) with an IC₅₀ value of 2.8 μM, and it also acts as an uncoupler of oxidative phosphorylation. Benzarone can cause liver damage and promote cell apoptosis and necrosis. Benzarone can be used to lower serum uric acid levels and for research in vascular diseases .

HY-146273

Xanthine oxidase-IN-7	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-7 (compound1h) is a potent andorally active *XO (xanthine* oxidase) inhibitor with an IC₅₀** of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout .

HY-108844

Rasburicase	Xanthine Oxidase	Metabolic Disease Cancer
Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout .

HY-P2921D

Uricase, candida utilis	Endogenous Metabolite	Metabolic Disease
Uricase, candida utilis is a peroxidase enzyme. It catalyzes the oxidation of uric acid, converting it into the soluble product allantoin. Uricase, candida utilis can be used for the determination of uric acid levels in serum. A deficiency of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, candida utilis can be utilized in research on gout and hyperuricemia .

HY-172778

HNW005	NOD-like Receptor (NLR) URAT1	Metabolic Disease Inflammation/Immunology
HNW005 is a dual inhibitor of NLRP3 inflammasome and urate transporter 1 (URAT1). It has a K_D value of 204.6 nM and an IC₅₀ of 1.7 μM for inhibiting NLRP3 inflammasome activation, and an IC₅₀ of 6.4 μM for inhibiting uric acid transmembrane transport. When administered at a dose of 2 mg/kg in vivo, HNW005 can achieve a uric acid reduction rate of 64.8%. It can exert anti - inflammatory, analgesic, and uric acid - lowering activities by inhibiting the activation of NLRP3 inflammasome and uric acid transmembrane transport. HNW005 can be used in the research of gouty arthritis .

HY-173231

hURAT1 inhibitor 2	URAT1	Metabolic Disease
hURAT1 inhibitor 2 (Compound 5) is an inhibitor of hURAT1 (uric acid transporter 1, SLC22A12) with an IC₅₀ of 18 nM. hURAT1 inhibitor 2 also has a certain inhibitory effect on OATP1B1, with an IC₅₀ value of 0.73 μM. hURAT1 inhibitor 2 can be used in the research of diseases related to abnormal uric acid metabolism, such as hyperuricemia and gout .

HY-161523

XOR/URAT1-IN-1	Xanthine Oxidase URAT1	Metabolic Disease
XOR/URAT1-IN-1 (Compound II15) is a dual inhibitor for xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1), with IC₅₀ of 6 nM and 12.9 μM. XOR/URAT1-IN-1 lowers the levels of uric acid in Potassium oxonate (HY-17511)/Hypoxanthine (HY-N0091)-induced acute hyperuricemia mouse model .

HY-W011258

H-Tyr-Phe-OH L-Tyrosyl-L-phenylalanine	Xanthine Oxidase Angiotensin-converting Enzyme (ACE)	Inflammation/Immunology Cancer
H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells .

HY-114309

URAT1 inhibitor 1	URAT1	Inflammation/Immunology
URAT1 inhibitor 1 (1g) is a uric acid transporter 1 (URAT1) inhibitor, with an IC₅₀ of 32 nM. URAT1 inhibitor 1 has potential to treat hyperuricemia associated with gout .

HY-W017386

3-Methyl-2-oxovaleric acid sodium 3 Publications Verification	Endogenous Metabolite	Metabolic Disease
3-Methyl-2-oxovaleric acid sodium is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid sodium is a biomarker of mustard airway diseases (MADs) and uric acid stone .

HY-113063

3-Methyl-2-oxovaleric acid 3 Publications Verification	Endogenous Metabolite	Metabolic Disease
3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone .

HY-W721656

Triclacetamol	Drug Derivative	Inflammation/Immunology
Triclacetamol is the trichloroacetyl derivative of Acetaminophen (HY-66005), exhibiting weak cyclooxygenase inhibition and possessing analgesic and antipyretic activities as a nonsteroidal anti-inflammatory drug (NSAID). Triclacetamol acts as an anti-inflammatory agent and promotes the excretion of uric acid .

HY-176139

URAT1 inhibitor 13	URAT1	Inflammation/Immunology
URAT1 inhibitor 13 (compound 22k) is a potent URAT1 inhibitor. URAT1 inhibitor 13 can be used in the study of gout .

HY-N10433

Xanthine oxidase-IN-9 Icarisids E	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-9 (Icarisids E) (Compound 2) is a potent xanthine oxidase (XOD) inhibitor with an IC₅₀ of 31.81 μM .

HY-B1514R

Allantoic acid (Standard)	Reference Standards Endogenous Metabolite	Others
Anagrelide (hydrochloride) (Standard) is the analytical standard of Anagrelide (hydrochloride). This product is intended for research and analytical applications. Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-174318

NARS-3′	Xanthine Oxidase	Metabolic Disease
NARS-3′ is a reversible xanthine oxidase (XO) inhibitor with the IC₅₀ of 21.01 μM. NARS-3′ can competitively inhibit XO activity and reduce uric acid production. NARS-3′ can reduce renal damage in hyperuricemia mice. NARS-3′ can be used for the study of hyperuricemia.

HY-168740

URAT1 inhibitor 11	URAT1	Metabolic Disease
URAT1 inhibitor 11 (Compound 7) is a URAT1 inhibitor with an IC₅₀ value of 0.18 μM. URAT1 inhibitor 11 exhibits potent hypouricemic effects in hyperuricemic zebrafish induced by Potassium oxonate (HY-17511) and Xanthine sodium salt (HY-W017389) .

HY-139585

Tigulixostat LC350189	Xanthine Oxidase	Metabolic Disease
Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC₅₀ values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia .

HY-162882

CC15009	Xanthine Oxidase Reactive Oxygen Species (ROS)	Metabolic Disease
CC15009 is a xanthine oxidoreductase (XOR) inhibitor, with an IC₅₀ value of 0.237 nM. CC15009 can inhibit the oxidative subtype of XOR, thereby reducing the production of the byproduct ROS and exhibiting antioxidant activity. CC15009 has demonstrated a good dose-dependent uric acid-lowering effect in two different mouse models of hyperuricemia induced by XOR substrates .

HY-119596

Eupatoriochromene	Xanthine Oxidase	Others
Eupatoriochromene is a chromene and has inhibitory activity against xanthine oxidase (XO) .

HY-152033

URAT1 inhibitor 4	URAT1 GLUT	Metabolic Disease
URAT1 inhibitor 4, a Lesinurad derivative, is a potent and orally active URAT1 inhibitor with an IC₅₀ of 7.56 μM. URAT1 inhibitor 4 has higher in vivo urate-lowering efficacy than Lesinurad (HY-15258) .

HY-W017386S

3-Methyl-2-oxovaleric acid-d8 sodium	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
3-Methyl-2-oxovaleric acid-d₈ sodium is the deuterium labeled 3-Methyl-2-oxovaleric acid. 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone .

HY-159718

NLRP3-IN-46	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-46 (Compound 3k) activates neuro-immunomodulatory cholinergic anti-inflammatory pathway, and thus inhibits NLRP3 inflammasome activation. NLRP3-IN-46 inhibits Uric acid sodium (HY-B2130A)-induced IL-1β production in THP-1 cells, and can be used in gouty arthritis research .

HY-113063R

3-Methyl-2-oxovaleric acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
3-Methyl-2-oxovaleric acid (Standard) is the analytical standard of 3-Methyl-2-oxovaleric acid (HY-113063). This product is intended for research and analytical applications. 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone.

HY-P10218A

MANS peptide TFA	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P10218

MANS peptide	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-W017389R

Xanthine (Standard)	Reference Standards Endogenous Metabolite	Inflammation/Immunology
Xanthine (Standard) is the analytical standard of Xanthine. This product is intended for research and analytical applications. Xanthine, a plant alkaloid found in tea, coffee, and cocoa, is a mild stimulant of the central nervous system. Xanthine also acts as an intermediate product on the pathway of purine degradation . In Vitro: A number of stimulants are derived from Xanthine including caffeine and theobromine. Xanthine is a product on the pathway of purine degradation. Xanthine is subsequently converted to uric acid by the action of the Xanthine oxidase enzyme.

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-169089

RP-182-PEG3-K(palmitic acid)	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-14874

Topiroxostat 5 Publications Verification FYX-051	Xanthine Oxidase Cytochrome P450	Metabolic Disease
Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC₅₀ value of 5.3 nM and a K_i value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment .

Cat. No.	Product Name	Type

HY-15933

TOPS	Indicators
TOPS is a chromogenic substrate. TOPS undergoes an oxidative coupling reaction with 4-aminoantipyrine in the presence of H₂O₂ and nanocrystalline cobalt selenide. TOPS is used in studies related to uric acid detection .

HY-W017386

3-Methyl-2-oxovaleric acid sodium 3 Publications Verification	Enzyme Substrates
3-Methyl-2-oxovaleric acid sodium is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid sodium is a biomarker of mustard airway diseases (MADs) and uric acid stone .

Cat. No.	Product Name	Target	Research Area

HY-W011258

H-Tyr-Phe-OH L-Tyrosyl-L-phenylalanine	Xanthine Oxidase Angiotensin-converting Enzyme (ACE)	Inflammation/Immunology Cancer
H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells .

HY-P10218A

MANS peptide TFA	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P10218

MANS peptide	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P10869

dCNP	Natriuretic Peptide Receptor (NPR)	Inflammation/Immunology Cancer
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-169089

RP-182-PEG3-K(palmitic acid)	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P4837

Ac-Lys-D-Ala-D-lactic acid	Peptides	Others
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P10200

CP7-FP13-2	Bacterial	Infection
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .

HY-P0041

F992	Vasopressin Receptor	Neurological Disease
F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P0041A

F992 TFA	Vasopressin Receptor	Neurological Disease
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P5161

FC382K10W15	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research .

HY-P5161A

FC382K10W15 TFA	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

HY-P3462

Cagrilintide 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P3462A

Cagrilintide acetate 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-P10271

RG7697	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P10381

palm11-TTDS-PrRP31	Peptides	Others
palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC₅₀: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .

HY-113560

Plipastatin B1	Antibiotic Fungal Phospholipase	Infection
Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A₂ (PLA2), which has antifungal activity .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

HY-P2595

SKF 103784	Peptides	Cardiovascular Disease
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P10031A

SAR441255 TFA	GLP Receptor GCGR	Metabolic Disease
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-P4895

(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin	Oxytocin Receptor	Neurological Disease
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .

HY-P10881

Ganipatide	Peptide-Drug Conjugates (PDCs)	Metabolic Disease
Ganipatide is a 1-31-Glucose-dependent insulinotropic polypeptide. Ganipatide is promising for research of diabetes .

HY-P10563

Noraramtide BHV-1100	CD38	Cancer
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .

Cat. No.	Product Name	Category	Target	Chemical Structure